These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33949932)

  • 1. Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib.
    Thakur S; Ruan Y; Jayanthan A; Boklan J; Narendran A
    Curr Cancer Drug Targets; 2021; 21(9):804-811. PubMed ID: 33949932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
    Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
    Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
    Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
    J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
    Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
    Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
    Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
    J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
    Swift L; Jayanthan A; Ruan Y; Anderson R; Boklan J; Trippett T; Narendran A
    Target Oncol; 2018 Dec; 13(6):779-793. PubMed ID: 30446871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
    Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
    J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
    Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
    Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
    Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
    Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
    Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
    PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
    Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
    Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
    Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
    Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
    Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
    Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
    Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
    Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
    Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
    Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
    Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
    Dietz A; Dalda N; Zielke S; Dittmann J; van Wijk SJL; Vogler M; Fulda S
    Int J Cancer; 2020 Sep; 147(5):1485-1498. PubMed ID: 32170726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.